AbbVie has formed a new collaboration with Valkai to enhance its artificial intelligence (AI) capabilities in clinical development. This partnership aims to improve efficiency in clinical research, accelerate insight generation, and reduce drug development timelines. By integrating Valkai's AI platform, AbbVie seeks to strengthen its data-driven innovation and expedite the delivery of new medicines to patients. This move reflects AbbVie's broader commitment to embedding AI across its operations to advance scientific progress and improve patient outcomes responsibly.
As of Sep 29, 2026 20:13 WIB, AbbVie Inc (ABBV) is trading at USD 266.00 on Pluang, showing a slight decrease of 0.15% over the day. The stock has a market capitalization of $470.55 billion and an enterprise value of $534.80 billion. Notably, the Pluang platform records a higher sell order activity at 71%, indicating cautious sentiment among investors at this time.
AbbVie announced FDA approval of JUVMO™ (tavapadon), the first selective D1/D5 receptor agonist for treating adults with Parkinson's disease. JUVMO offers a novel approach to motor symptom control, improving daily functioning and increasing 'on' time...
AbbVie and Johnson & Johnson are both strong dividend stocks trading near their 52-week highs, but they differ significantly in risk and growth. AbbVie shows faster revenue growth and a higher dividend yield, driven by its immunology drugs, but faces...
